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Introduction
Short-term intravascular access devices, which include 
central venous and arterial catheters, are commonly used 
for the management of critically ill patients with the major-
ity of patients receiving care that involves the use of these 
catheters (Curtis, 2009). The use of intravascular catheters 
is, however, associated with the risk of bloodstream infec-
tions (BSI); a leading cause of healthcare-associated infec-
tions (HCAI). In a recent survey reported by the Health 
Protection Agency (now Public Health England) blood 
Economic impact of Tegaderm 
chlorhexidine gluconate (CHG)  
dressing in critically ill patients
Praveen Thokala1, Martin Arrowsmith2, Edith Poku1,  
Marissa Martyn-St James1, Jeff Anderson3, Steve Foster2,  
Tom Elliott4 and Tony Whitehouse4
Abstract
Purpose: To estimate the economic impact of a TegadermTM chlorhexidine gluconate (CHG) gel dressing compared 
with a standard intravenous (i.v.) dressing (defined as non-antimicrobial transparent film dressing), used for insertion site 
care of short-term central venous and arterial catheters (intravascular catheters) in adult critical care patients using a 
cost-consequence model populated with data from published sources.
Material and Methods: A decision analytical cost-consequence model was developed which assigned each patient 
with an indwelling intravascular catheter and a standard dressing, a baseline risk of associated dermatitis, local infection 
at the catheter insertion site and catheter-related bloodstream infections (CRBSI), estimated from published second-
ary sources. The risks of these events for patients with a Tegaderm CHG were estimated by applying the effective-
ness parameters from the clinical review to the baseline risks. Costs were accrued through costs of intervention (i.e. 
 Tegaderm CHG or standard intravenous dressing) and hospital treatment costs depended on whether the patients had 
local dermatitis, local infection or CRBSI. Total costs were estimated as mean values of 10,000 probabilistic sensitivity 
analysis (PSA) runs.
Results: Tegaderm CHG resulted in an average cost-saving of £77 per patient in an intensive care unit. Tegaderm CHG 
also has a 98.5% probability of being cost-saving compared to standard i.v. dressings.
Conclusions: The analyses suggest that Tegaderm CHG is a cost-saving strategy to reduce CRBSI and the results were 
robust to sensitivity analyses.
Keywords
Tegaderm chlorhexidine gluconate (CHG), cost-effectiveness, vascular access, bloodstream infection, catheter-related 
bloodstream infection (CRBSI), adult critical care, cost model, central venous catheter (CVC), arterial catheters, 
chlorhexidine dressing
Date received: 15 October 2015; accepted: 28 May 2016
1Health Economics and Decision Science, School of Health and Related 
Research, The University of Sheffield, Sheffield, UK
23M United Kingdom PLC, Morley St, Loughborough, UK
3Evidera, Metro Building, London, UK
4University Hospitals Birmingham NHS Foundation Trust, Queen 
Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK
Corresponding author:
Praveen Thokala, University of Sheffield, 30 Regent Street, Sheffield, S1 
4DA, UK. 
Email: p.thokala@sheffield.ac.uk
657162 BJI0010.1177/1757177416657162Journal of Infection PreventionThokala et al.
research-article2016
Original Article
Thokala et al. 217
stream infections accounted for 7.3% of all HCAI and of 
these 64% were in patients with a vascular access device 
(Health Protection Agency, 2011).
Infections associated with intravascular catheters are 
often categorised as either central-line associated blood-
stream infection (CLABSI) or catheter-related bloodstream 
infection (CRBSI). The former term is often used in rela-
tion to epidemiological studies on the surveillance of 
bloodstream infections and the latter where a high degree 
of confidence in the origins of the infection is determined. 
The Centers for Disease Control and Prevention (CDC) 
recommends the CLABSI definition be used for surveil-
lance of infections and defines it as: a confirmed BSI in any 
patient with a central venous catheter (CVC) present either 
at the time of or within a 48-h period before the detection of 
infection. CLABSI are likely therefore to overestimate the 
incidence of CRBSI, as they do not fully confirm the source 
of infection as the intravascular catheter. CRBSI is more 
frequently used in clinical research being a more precise 
and rigorous definition that requires isolation of the same 
microorganism from the catheter tip and peripheral blood 
or other validated methods including comparison of the 
numbers of microorganisms present in peripheral blood 
with samples obtained through the catheter or the differen-
tial time to positivity of blood obtained via the catheter ver-
sus peripheral blood (Chopra et al., 2013). For the purposes 
of this report we have used a single term and describe both 
CRBSI and CLABSI as CRBSI.
The risk of CRBSI is associated with a variety of factors 
including the site of insertion of the device and the severity 
of the patients underlying clinical condition. In 2009, the 
CDC estimated the number of CRBSI in intensive care 
units (ICUs) across the United States to be 18,000 
(Srinivasan et al., 2011). In a pan-European survey of ICU 
patients, the incidence of CRBSI was in the range of 1–3.1 
per 1000 patient days (Suetens et al., 2007). The reported 
incidence of CRBSI has decreased in more recently reported 
studies following various interventions including a care 
bundle approach. For example, in a national critical care 
programme in the UK, the incidence of CRBSI fell from 
3.7 to 1.48 per 1000 patient days (Bion et al., 2013). 
However, CRBSI are still associated with attributable mor-
tality rates of up to 11.5% and may extend ICU stay by up 
to 12 days (Renaud and Brun-Buisson, 2001; Soufir et al., 
1999). Each CRBSI has been estimated to cost $16,550 and 
initiatives to reduce this complication raise the possibility 
of substantial savings (O’Grady et al., 2011).
More recently, improvements in quality of care have 
focused on initiatives with a care bundle of evidence-based 
interventions. For example, the introduction of a central 
venous insertion bundle into multiple ICUs in Michigan, 
which included implementation and close monitoring of 
hand hygiene, the application of chlorhexidine skin prepa-
rations and the use of the subclavian vein resulted in a 
decrease of CR-BSI by 66% (Pronovost et al., 2006).
Many interventions are included in the current guidelines 
for insertion and care of CVCs. The guidelines available 
include those from the UK’s National Institute for Health 
and Care Excellence (NICE) relating to infections in pri-
mary care (NICE, 2012), epic3 which present national 
guidelines primarily for hospitals in UK (Loveday et al., 
2014) and the Healthcare Infection Control Practices 
Advisory Committee (HICPAC) guidelines in US (O’Grady 
et al., 2011). The interventions recommended include: full 
barrier precautions during insertion; use of a 2% chlorhex-
idine gluconate in alcohol for care of the catheter insertion 
site; the application of sterile transparent dressings to cover 
the insertion site with replacement at least every 7 days; and 
the use of alcohol to disinfect hubs and ports prior to access.
Additional approaches to prevent CRBSI have included 
the introduction of new technological innovations, including 
antiseptic impregnated central catheters and chlorhexidine 
impregnated sponge dressings, which have also been associ-
ated with significant reductions in infection rates (Casey 
et al., 2008; Timsit et al., 2009). In certain healthcare institu-
tions, where both bundle interventions and technological 
solutions have been implemented, the prospect of zero CRBSI 
is considered to be a potential goal. (Zingg et al., 2011).
More recently, the epic3 updated guideline included the 
recommendation to use a 2% chlorhexidine gel dressing for 
intravascular catheters (Loveday et al., 2015). The purpose 
of the current study was to develop a model to evaluate the 
economic value of implementing such a 2% chlorhexidine 
gel dressing in the care of insertion sites associated with 
CVC and arterial catheters in critically ill adult patients. 
There is a paucity of studies which have demonstrated cost-
savings with individual infection prevention interventions. 
In the UK, NICE (NICE, 2011) uses cost-consequence 
analysis to evaluate medical devices. We therefore used a 
similar approach to estimate the cost impact of introducing 
Tegaderm chlorhexidine gluconate (CHG) dressing (3M 
Health Care, Loughborough, UK) into clinical practice in 
adult critical care. The Tegaderm CHG dressing delivers 
chlorhexidine over 7 days from an integrated gel pad placed 
over the point of insertion of an intravascular catheter. A 
previous study (Timsit et al., 2012) has suggested it is asso-
ciated with significant reductions in CRBSI compared to 
standard, non-medicated, transparent film dressings (stand-
ard intravenous [i.v.] dressings). This paper describes a 
decision analytic model, informed by parameters derived 
from published data, which has been used to estimate costs 
associated with the use of Tegaderm CHG i.v. dressings 
compared with standard i.v. dressings.
Material and methods
A decision analytical model (Petrou et al., 2011) was devel-
oped using Microsoft Excel software (Microsoft 
Corporation) to estimate the economic impact of a 
Tegaderm CHG dressing when compared with standard i.v. 
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dressings (defined as standard non-antimicrobial transpar-
ent film dressings) for patients admitted to an ICU requir-
ing an intravascular catheter. The economic perspective of 
the model is the National Health Service (NHS) in England 
and Wales. The model used a short time horizon and the 
structure of the model is shown in Figure 1.
The model assigned each patient with an indwelling 
intravascular catheter and a standard i.v. dressing, a base-
line risk of associated dermatitis, local infection at the cath-
eter insertion site and CRBSI. The risks of these events for 
patients with a Tegaderm CHG were estimated by applying 
the effectiveness parameters derived from the published lit-
erature to the baseline risks. Costs were accrued through 
costs of intervention (i.e. Tegaderm CHG or standard i.v. 
dressing) and hospital treatment costs depended on whether 
the patients had dermatitis, local infection or CRBSI. 
Results were estimated as mean values of 10,000 probabil-
istic sensitivity analysis (PSA) runs, each run with a differ-
ent estimate for the risks, hazard ratios (HR) and costs 
sampled from probability distributions representing uncer-
tainty in the parameter estimates.
Baseline risks
Baseline risks were estimated using data from existing med-
ical literature. The outcomes included in the model were: (1) 
CRBSI; (2) local site infection; and (3) dermatitis.
The baseline primary outcome measure, CRBSI, was 
estimated from ‘Matching Michigan’: a 2-year study of 
central venous CRBSI in ICUs in England (Bion et al., 
2013). This study reported an average rate of 1.48 catheter-
related infections per 1000 adult catheter days, which is 
similar to the rate reported in other studies (Edwards et al., 
2009; Timsit et al., 2012). The average length of stay in an 
ICU for a patient with a catheter has been estimated to be 
10 days, a value that has been used in another economic 
analysis (Ye et al., 2011). In the economic model, CRBSI 
risk per patient was estimated by multiplying this length of 
stay by the CRBSI rate which resulted in a mean CRBSI 
risk of 0.0148 per patient.
A key secondary outcome measure of interest was the 
local site infection rate. There are substantially different esti-
mates of incidence reported in various sources, with inci-
dence in the range of 10–30%. Crawford et al. (2004) used a 
local infection rate of 18.1% in their economic analysis and 
Vokurka et al. (2009) reported a rate of local site infection of 
30%. However, Pemberton et al. (1996) reported the rate of 
local site infection as 10% when using non-antimicrobial 
transparent film dressings. This figure was also used in the 
economic analysis by Ye et al. (2011) concerning an antimi-
crobial patch. In this current economic model, a conservative 
estimate of a mean local site infection rate of 10% was used 
as shown in Table 1 for the base case analysis.
Another outcome of interest was dermatitis. A dermatitis 
rate of 1.1% was associated with the use of Tegaderm CHG 
as compared to 0.29% for standard dressings (Timsit et al., 
2012). However, this study was undertaken using a first 
generation version of the Tegaderm CHG dressing that 
appears to have a higher occurrence of this type of adverse 
event compared to the current version of the dressing that 
utilises a higher permeability film backing. Indeed, the 
introduction of a second generation Tegaderm CHG dress-
ing was associated with a reduction in the number of skin 
reactions reported in Manufacturer and User Facility 
Device Experience from 2010 to 2012, and in numbers that 
were comparable to CHG sponge dressings (Jenks et al., 
2015). In a study by Schwebel et al. (2012) on the clinical 
use of a CHG sponge dressing, a rate of device-related der-
matitis of 1.1 and 4.1/1000 catheters for a 3 and 7 days 
CHG dressing change protocol, respectively, was reported. 
The rate of dermatitis in the current model was assumed to 
be the average of these two dressing change frequencies. In 
this current study, a mean dermatitis rate of 2.6/1000 cath-
eters associated with the use of Tegaderm CHG dressing 
was therefore used as shown in Table 1.
Effectiveness of Tegaderm CHG
The effectiveness parameters for Tegaderm CHG dressing 
were estimated from Timsit et al. (2012), the only relevant 
study identified in a systematic review which was under-
taken in accordance with recommendations in the Preferred 
Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) statement. The purpose of the review was to 
identify studies evaluating the effectiveness and safety of 
3M Tegaderm CHG dressings compared to standard i.v. 
dressings used in routine care of patients (age >18 years) 
Figure 1. Model structure.
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admitted to a critical care setting such as an ICU who 
required intravascular access—via an arterial catheter or 
CVC or both—for at least 24 h. The details of the search 
strategy used are provided in the appendix.
HRs estimated from Timsit et al. (2012) were used as 
effectiveness parameters in the model for Tegaderm CHG 
dressing. As used in Ye et al. (2011), the HR for local site 
infection was assumed to be the same as the HR for CRBSI. 
The probabilities of developing a CRBSI and local infec-
tions for patients given Tegaderm CHG dressing were esti-
mated by applying the HRs to the baseline parameters. For 
dermatitis, the effectiveness of Tegaderm CHG dressing 
was modelled as a relative risk (RR) and the probability of 
dermatitis for patients with Tegaderm CHG dressing were 
estimated by applying the RR to the baseline dermatitis 
probability.
Costs
The costs included in the model are the costs of the dress-
ings and those associated with the treatment, where appro-
priate, for any local infections at the catheter insertion site, 
CRBSI and dermatitis. It was assumed that all other initial 
treatment costs were the same and were not included in the 
model. The Tegaderm CHG dressing is readily adopted into 
clinical practice and can directly replace standard i.v. dress-
ing in the care pathways for arterial and CVCs. Therefore, 
no additional staff costs were included in the model.
The cost of standard care was estimated as the number of 
standard i.v. dressings required multiplied by the unit cost of 
this standard i.v. dressing. The number of dressings required 
was estimated by dividing the average duration of stay of a 
patient with a catheter on ICU in situ by the average dress-
ing duration. The average length of stay for a patient with an 
intravascular catheter in situ on ICU was estimated to be 10 
days (Ye et al., 2011) and with the prescribed time for stand-
ard i.v. dressing being between 3 and 7 days, this resulted in 
three standard i.v. dressings required per patient. The unit 
cost of a standard i.v. dressing was £1.34, as shown in Table 
1 and thus, in the model, the average cost of standard i.v. 
dressings per patient was calculated to be £4.02.
The cost of using Tegaderm CHG dressings per patient 
was estimated as the number of Tegaderm CHG dressings 
required multiplied by the unit cost of the Tegaderm CHG 
dressing. The unit cost of Tegaderm CHG dressing was 
£6.21 for the NHS as shown in Table 1. Again, the number 
of dressings required was estimated by dividing the average 
length of stay of a patient on an ICU with a catheter by the 
average dressing duration. The average length of stay of a 
patient on an ICU with an indwelling intravascular catheter 
was taken as 10 days (Ye et al., 2011) and an estimate of 
three dressings per patient resulted in the average cost of 
Tegaderm CHG dressings per patient being £18.63.
The main cost driver included in the model was the cost 
of CRBSI, which included costs of diagnosis, catheter 
replacement and the costs associated with increased length 
Table 1. Summary of model parameters.
Parameter Mean Distribution Source
Average length of catheterisation 10 days Normal (10, 2) Timsit et al., 2012
Baseline risks
CRBSI risk (per 1000 catheter days)
Local site infection risk (per patient)
Dermatitis risk (per catheter)
1.48/1000 catheter days
0.1
0.0026
Normal (1.48, 0.075)
Normal (0.1, 1)
Normal (0.0026, 0.0002)
Bion et al., 2013
Ye et al., 2011
Schwebel et al., 2012, 
Timsit et al., 2012
HRs for Tegaderm CHG
CRBSI
Local site infection
Dermatitis (as RR)
0.402
0.402
4.4
Lognormal (–0.911, 0.393)
Lognormal (–0.911, 0.393)
Lognormal (1.482, –0.489)
Timsit et al., 2012
Timsit et al., 2012
Timsit et al., 2012
Costs (in £)
Unit cost of standard i.v. dressings
Unit cost of Tegaderm CHG 
dressings
CRBSI
Local site infection
Dermatitis
£1.34
£6.21
£9900
£250
£150
Fixed
Fixed
Gamma (198, 50)
Gamma (50, 5)
Gamma (30, 5)
3M
3M
Hockenhull et al., 2008
Saint et al., 2000
Schwebel et al., 2012
Normal distribution is represented with mean and SD, with 95% of the values in the distribution lying between 2 SDs on either side of the mean, e.g. 
normal (10, 2) implies that 95% of the samples lie between 6 and 14. Lognormal distribution is a continuous probability distribution whose logarithm 
is normally distributed. Gamma (a, b) distribution, where a is the shape parameter and b is the scale parameter, is typically used for skewed distribu-
tions and has a mean expected value of a × b, e.g. the average value of the samples of distribution Gamma (198, 50) is 9900 (i.e. 198 × 50).
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of stay. Schwebel et al. (2012) reported that the mean addi-
tional hospital length of stay for patients with CRBSI is 11 
days, which resulted in a reported cost estimate of CRBSI 
in excess of $25,000 (Schwebel et al., 2012; Ye et al., 2011). 
In Europe, additional length of stay in ICU has been 
reported as 9–10 days (Timsit et al., 2012). However, this 
was regarded as longer than that seen in many ICUs in the 
UK by our clinical experts (the co-authors of this manu-
script), who considered that the average length of stay for a 
CRBSI patient will vary between 6 days (first 2 days in 
ICU and the remaining 4 days in a general medical ward) 
and 10 days (first 3 days in ICU and the remaining 7 days 
in a general medical ward). In a UK hospital, the cost of an 
average day in the ICU has been determined as being in the 
range of £1800–2400 with an additional £100 for the con-
sultant time and consumables. This figure, in combination 
with the extra ward based costs of £480 per day, results in 
an average extra total cost of around £9750. Also, it is esti-
mated that in clinical practice approximately 50% of intra-
vascular catheters are removed due to suspected CRBSI 
and if they are subsequently replaced the cost is estimated 
to be £140 (acquisition cost of catheter £35; X-ray for con-
firming position of catheter £50 plus consumables of £15 
plus staff costs to carry out the procedure at £40). In view 
of this, a figure of £140 for catheter replacement has been 
included in the total cost of CRBSI, which results in the 
overall CRBSI cost of £9890. This figure is very similar to 
that used in a Health Technology Assessment (HTA) 
(Hockenhull et al., 2008) who reported a mean CRBSI cost 
of £9148, that when inflated to present day costs using the 
hospital and community health services (HCHS) pay and 
price index (Curtis, 2013) is £9905. Thus, the cost of 
CRBSI used in the model is £9900 as shown in Table 1.
The cost of treatment for a local site infection was 
reported as $400 (Saint et al., 2000) and it was considered 
that a cost of £250 for treatment of local infection in UK 
was a reasonable estimate and was therefore adopted in the 
model as shown in Table 1.
The costs of treating dermatitis were taken from 
Schwebel et al. (2012), who reported that contact dermatitis 
requires four standard i.v. dressings, removal of the catheter 
and insertion of a new catheter. They used a micro-costing 
approach to estimate the total costs as $228. We considered 
that the equivalent cost of £150 for treatment of dermatitis 
was acceptable and this was used in the model as shown in 
Table 1.
Summary of model parameters
The decision analytic model assigned a baseline risk of dif-
ferent events for each patient with standard i.v. dressing. 
The risks of these events for patients with Tegaderm CHG 
dressing were estimated by applying the HRs from pub-
lished literature to the baseline risks. A summary of the 
model parameters is provided in Table 1, along with their 
sources. The scope of this study was adult intensive care 
patients.
Results
First, we estimated the mean event rates that would be 
expected in a typical patient if Tegaderm CHG dressing 
were implemented instead of standard care. Tegaderm 
CHG dressing reduces the all event rates per patient except 
for dermatitis (Table 2). It is of note that the formulation of 
the Tegaderm CHG dressing was changed in 2011 to 
include a more permeable film on the back. The introduc-
tion of second generation Tegaderm CHG dressing was 
associated with a reduction in the number of skin reactions 
reported in Manufacturer and User Facility Device from 
2010 to 2012 (FDA, 2014).
We then estimated the costs that would be expected in a 
typical service for 1000 adult patients who require a short-
term intravascular catheter located in an ICU where 
Tegaderm CHG dressing was the routine dressing instead 
of a standard i.v. dressing. Results were estimated as mean 
values of 1000 probabilistic sensitivity analysis runs, each 
run with a different estimate for the risks, HRs and costs 
sampled from the probability distributions reported in 
Table 1. The model showed use of Tegaderm CHG dressing 
results in an overall saving of £77,427 per 1000 patients, 
i.e. an average cost saving of £77 (95% CI, £76.70–78.10) 
per adult patient. The Tegaderm CHG dressing therefore 
has a 98.5% probability of being cost-saving compared to 
standard i.v. dressings.
The total cost-savings is provided as a breakdown of the 
individual cost differences as shown in Table 3. Most of the 
savings described are due to a reduction in suspected and 
confirmed CRBSI. There are higher costs associated with 
the acquisition of CHG dressings but the savings in reduced 
event rates more than offset these costs associated with the 
technology, as seen in Figure 2.
One-way sensitivity analysis was performed on all the 
model parameters. The baseline CRBSI risks and unit cost 
Table 2. Summary of clinical risks associated with either the 
standard i.v. dressing or Tegaderm CHG.
Clinical risk
Standard i.v. 
dressing
Tegaderm 
CHG
CRBSI risk 1.48 per 1000 
catheter days
0.6 per 1000 
catheter days
Local site infection risk 
(per patient)
10% 4.25%
Dermatitis risk (per 
patient)
0.26% 1.11%
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of CRBSI were identified as the key cost drivers while the 
rest of the parameters did not have an impact on the results 
or conclusions. Thus, only the results of sensitivity analysis 
for CRBSI risks and costs are presented here. At a lower 
CRBSI baseline risk of 0.5 per 1000 catheter days, the 
mean cost savings were £22,747 and at a higher estimate of 
2.5 per 1000 catheter days, the mean cost savings were 
£133,591. At a lower cost estimate of CRBSI of £5000, the 
mean cost savings were £36,174 while the cost savings 
were £119,040 at a higher estimate of £15,000. Thus the 
lower the CRBSI baseline risk and cost of CRBSI, the 
lower the cost savings. Similarly, the higher the baseline 
risk of CRBSI and the cost of CRBSI, the higher the aver-
age cost savings. Threshold analysis conducted suggested 
that the baseline CRBSI risk has to be lower than 0.1 per 
1000 catheter days for Tegaderm CHG dressing to not be 
cost-saving.
Discussion
Our analyses suggest that Tegaderm CHG dressing is a 
cost-saving strategy when implemented for care of adult 
patients with intravascular catheters in ICU. Tegaderm 
CHG dressing results in an overall savings of £77,427 per 
1000 adult patients, i.e. an average cost saving of £77 per 
patient compared to standard care with a 98.5% probability 
of being cost-saving compared to standard i.v. dressings. A 
12-bed ICU is estimated to admit approximately 770 
patients each year, the majority of whom will receive an 
intravascular catheter. The estimated cost savings for 
replacement of standard i.v. dressings with Tegaderm CHG 
dressing in such a unit is £59,600 per annum. The results 
were robust to sensitivity analyses performed on the base-
line CRBSI risks and unit cost of CRBSI. These average 
cost-savings reported are for units that follow the English 
national trend for incidence of CRBSI reported by Bion 
et al. (2013). Interestingly, the model also indicates that 
cost-savings can be found even in units with levels of 
CRBSI as low as 0.33 per 1000 catheter days.
Dermatitis has been identified as an adverse event that 
has a higher risk for CHG containing dressings compared 
to standard i.v. dressings. The results from this study indi-
cate that the costs associated with the management of the 
related dermatitis per patient has a mean of £4.66. Another, 
albeit uncommon but potentially serious, adverse event 
associated with the use of chlorhexidine containing prod-
ucts is anaphylaxis (MHRA, 2012). However, no systemic 
adverse events associated with use of Tegaderm CHG 
dressing were reported during a comparative study includ-
ing 1879 adult patients (Timsit et al., 2012) and the poten-
tial costs associated with anaphylaxis were not included in 
the model. It is of note that Tegaderm CHG dressing is not 
indicated for use in patients aged under 2 months and our 
study only included adult patients.
There are other published analyses studies of CHG 
impregnated devices including CHG dressings, but to date 
none of them included Tegaderm CHG gel dressing. The 
analysis reported by Veenstra et al. (1999) compared the 
number of CRBSIs associated with CHG impregnated and 
standard intravascular catheters and suggested that antisep-
tic impregnated catheters are cost-saving. Crawford et al. 
(2004) performed a trial based evaluation and concluded 
that CHG sponge dressings would reduce costs, local infec-
tions and CRBSIs, and associated mortality. Similarly, 
Hockenhull et al. (2008) developed a decision analytic 
model for patients requiring CVCs in the UK and suggested 
that antimicrobial CVCs are cost-saving. More recently, Ye 
et al. (2011) suggested that a CHG dressing is also a cost-
effective CRBSI prevention treatment option. Furthermore, 
Schwebel et al. (2012) performed a trial based evaluation 
Table 3. Breakdown of cost results.
Standard i.v. Dressing Tegaderm CHG Difference
Dressing costs £4021 £18,631 £14,610
CRBSI £146,457 £63,603 –£82,854
Local site infection £24,997 £11,153 –£13,844
Dermatitis £1166 £5826 £4660
Total costs £176,639 £99,212 –£77,427
Figure 2. Breakdown of the different costs for standard and 
Tegaderm CHG dressings (for a cohort of 10,000 patients).
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comparing both 3- and 7-day CHG dressing with standard 
dressings and concluded that CHG dressings are associated 
with financial savings. Our findings for Tegaderm CHG 
dressing are, therefore, in line with those reported in previ-
ous studies for antimicrobial devices used to prevent cathe-
ter-related infections.
The analysis reported in this paper has some limitations. 
Any modelling process involves simplifications and assump-
tions that may not accurately reflect local clinical practice. 
Owing to the lack of detail of cost estimates in research stud-
ies included in the analysis, scenarios were developed and 
their costs were independently reviewed by members of the 
research team. The uncertainties about the assumptions made 
in the estimation of these costs (especially CRBSI costs) 
were tested using scenario analysis and the conclusion that 
Tegaderm CHG dressing is cost-saving remains valid in 
these analyses. Threshold analysis performed suggested that 
the findings are robust and that large fluctuations in the 
CRBSI rates and cost parameters are needed before Tegaderm 
CHG dressing becomes cost incurring.
The results of the current analysis have important impli-
cations for the healthcare systems facing rising demand 
from emergency admissions into ICUs. The evidence sug-
gests that the use of Tegaderm CHG dressing may substan-
tially reduce the incidence of CRBSI and in doing so 
reduce the length of stay on an adult ICU and in subse-
quent clinical areas. This would also reduce the need for 
the use of antibiotic therapy and the risk of emergence of 
antimicrobial resistant microorganisms. The introduction 
of Tegaderm CHG dressings may also alleviate some pres-
sure on acute beds and have associated consequent cost-
savings. In concurrence with these findings, NICE has 
recently issued guidance suggesting that Tegaderm CHG 
dressing is cost-saving for the NHS in England and Wales 
(NICE, 2015).
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